San Diego — Data from an open-label extension study of delgocitinib cream reflects the positive phase 3 safety and efficacy results released > 1 year ago from two separate trials in patients with ...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced the positive outcome of the DELTA 3 trial. DELTA 3 is a phase 3, single-arm, open-label ...